SLC5A2 and type 2 diabetes mellitus: Robust evidence of the safety of SGLT2 inhibitors within bone health is warranted, although both empagliflozin and dapagliflozin are currently being favored in T2DM patients with known bone fragility, as the available data on both of them has not raised similar concerns [2].